Reactions 1704, p157 - 2 Jun 2018
Anal melanoma: case report
A 65-year-old man developed anal melanoma following
treatment with etanercept and infliximab for rheumatoid
arthritis [routes, dosages and durations of treatments to
reaction onset not stated].
The man, who had a history of rheumatoid arthritis,
presented with rectal bleeding and intermittent anal pain.
Examination showed a small, violaceous lesion over the
anterior anal verge. Excision of the lesion was performed and
pathology revealed a deep and ulcerated malignant melanoma.
Subsequently, the man underwent a wide local excision with
adequate margins. He reported using etanercept for 15 years
and a recent switch to infliximab for rheumatoid arthritis.
Infliximab was discontinued upon diagnosis of the melanoma.
Author comment: "The risk factors for malignant
melanoma are well-established, yet the risk factors for anal
melanoma are less clear. In this case, the history of TNF
inhibitor use provides a possible risk factor.. . . This link
between TNF inhibitor use and the development of
melanoma may provide a clue to the etiology of anal
Kawak S, et al. A diagnosis of cutaneous anal melanoma after long-term TNF
inhibitor use. Diseases of the Colon and Rectum 61: e125, No. 5, May 2018.
Available from: URL: http://doi.org/10.1097/DCR.0000000000001104 [abstract] -
Reactions 2 Jun 2018 No. 17040114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved